Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Expands Leadership Team with the Hiring of Two Seasoned Executives
NanoString Expands Leadership Team with the Hiring of Two Seasoned Executives   Added Experience in Quality, Regulatory and Legal Supports Diagnostics Business SEATTLE | February 28, 2013 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and
View HTML
Toggle Summary NanoString Technologies Announces Positive Results from Second Validation Study of PAM50-based Breast Cancer Assay
NanoString Technologies Announces Positive Results from Second Validation Study of PAM50-based Breast Cancer Assay Study Demonstrates Ability of PAM50 Assay to Indicate Risk of Recurrence in Women with HR+ Early-Stage Breast Cancer Treated with Endocrine Therapy Alone SEATTLE, Wash.
View HTML
Toggle Summary NanoString Technologies Completes $15.3 Million Series E Financing
NanoString Technologies Completes $15.3 Million Series E Financing   SEATTLE, Wash. | December 3, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced the completion of a
View HTML
Toggle Summary NanoString Technologies Announces Presentation of Three Studies on PAM50-based Breast Cancer Assay at 2012 CTRC-AACR San Antonio Breast Cancer Symposium
NanoString Technologies Announces Presentation of Three Studies on PAM50-based Breast Cancer Assay at 2012 CTRC-AACR San Antonio Breast Cancer Symposium   SEATTLE, Wash., and San Antonio, TX | December 3, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for
View HTML
Toggle Summary NanoString Technologies Appoints James A. Johnson as Chief Financial Officer
NanoString Technologies Appoints James A. Johnson as Chief Financial Officer   Industry Veteran Brings More Than 20 Years of Life Sciences Financial Expertise SEATTLE, Wash. | October 3, 2012 – NanoString Technologies, Inc., a privately-held provider of life science tools for translational research
View HTML
Toggle Summary NanoString Technologies Obtains CE Mark for PAM50-based Test for Breast Cancer
NanoString Technologies Obtains CE Mark for PAM50-based Test for Breast Cancer   Testing Kit Available in Early 2013 Will Offer EU Patients Risk of Recurrence Score and Intrinsic Subtyping SEATTLE, Wash | September 27, 2012 – NanoString Technologies, Inc., a privately held provider of life science
View HTML
Toggle Summary The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50
The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50   Online Publication in Journal Nature Shows PAM50 Potentially Simplifies Underlying Tumor Biology SEATTLE, Wash. | September 24, 2012 – On September 23, researchers published online in the journal Nature a
View HTML
Toggle Summary The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50
The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50   Online Publication in Journal Nature Shows PAM50 Potentially Simplifies Underlying Tumor Biology SEATTLE, Wash. | September 24, 2012 – On September 23, researchers published online in the journal Nature a
View HTML
Toggle Summary NanoString Technologies Names Dale R. Levitzke Vice President of Global Sales for Life Sciences
NanoString Technologies Names Dale R. Levitzke Vice President of Global Sales for Life Sciences   SEATTLE, Wash. | August 7, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the
View HTML
Toggle Summary NanoString Technologies Appoints Senior Financial Executive Greg Norden to Board of Directors
NanoString Technologies Appoints Senior Financial Executive Greg Norden to Board of Directors   Seattle, WA | July 18, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the
View HTML